Table 1 The baseline characteristics of included studies
Author | Year | Publication type | Source of analyzed data | Country | Cancer type | Sample size | Immunotherapy regimen | BMI stratification | Outcomes |
|---|---|---|---|---|---|---|---|---|---|
Ichihara (cohort 1) | 2020 | Full text | Retrospective cohort | Japan | NSCLC | 84 | Cohort1: pembrolizumab | High: ≥ 22.0; low: < 22.0 | OS, PFS |
Ichihara (Cohort 2) | 2020 | Full text | Retrospective cohort | Japan | NSCLC | 429 | Cohort2: nivolumab, pembrolizumab, atezolizumab | High: ≥ 22.0; low: < 22.0 | OS, PFS |
Popinat | 2019 | Full text | Retrospective cohort | France | NSCLC | 55 | Nivolumab | High: ≥ 24.7; low: < 24.7 | OS |
Magri | 2019 | Full text | Retrospective cohort | Israel | NSCLC | 46 | Nivolumab | High: ≥ 24.6; low: < 24.6 | OS |
Kulkarni | 2019 | Abstract | Retrospective cohort | USA | NSCLC | 148 | Nivolumab | High: ≥ 25.0; low: < 25.0 | OS, PFS |
Kichenadasse | 2019 | Full text | NCT02031458 NCT01846416 | USA, Australia | NSCLC | 1434 | Atezolizumab | Normal: 18.5–24.9 overweight: 25.0–29.9 obese: ≥ 30 | OS, PFS, IRAEs |
Zhi | 2018 | Abstract | Retrospective cohort | USA | NSCLC | 703 | Nivolumab, pembrolizumab | Normal: 18.5–24.9; overweight: 25.0–29.9; obese: ≥ 30 | OS, PFS |
Wang | 2019 | Full text | Retrospective cohort | USA | NSCLC Melanoma OC | 250 | PD-L1 inhibitor | High: ≥ 30; low: < 30 | OS, PFS |
Cortellini | 2019 | Full text | Retrospective cohort | Italy | NSCLC RCC melanoma | 976 | Pembrolizumab, nivolumab, atezolizumab | Definition1: high: ≥ 25.0; low: < 25.0 definition2: Normal: 18.5–24.9; overweight: 25·0–29.9; Obese: ≥ 30 | OS, PFS, IRAEs |
Naik | 2019 | Full text | Retrospective cohort | USA | Melanoma | 139 | PD-1 inhibitor | High: 25.0–35 low: < 25 | OS, PFS |
Richtig | 2018 | Full text | Retrospective cohort | Austria | Melanoma | 76 | Ipilimumab | High: ≥ 25.0; Low: < 25.0 | OS, PFS |
McQuade (cohort 1) | 2018 | Full text | NCT00324155& retrospective corhot | USA, Australia | Melanoma | 207 | Cohort 1: Ipilimumab plus dacarbazine | Normal: 18.5–24.9; overweight: 25.0–29.9; Obese: ≥ 30 | OS, PFS, IRAEs |
McQuade (Cohort 2) | 2018 | Full text | NCT00324155& Retrospective corhot | USA, Australia | Melanoma | 329 | Cohort 2: Pembrolizumab, nivolumab, atezolizumab | Normal: 18.5–24.9; Overweight: 25.0–29.9; Obese: ≥ 30 | OS, PFS, IRAEs |
Labadie | 2019 | Full text | Retrospective cohort | USA, Canada, Spain | RCC | 90 | Pembrolizumab, nivolumab, atezolizumab | Normal: 18.5–24.9 Overweight: 25.0–29.9 Obese: ≥ 30 | OS, PFS |
De Giorgi | 2019 | Full text | Retrospective cohort | Italy | RCC | 313 | Nivolumab | high: ≥ 25.0; low: < 25.0 | OS |